Cargando…

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) in an aggressive malignancy with suboptimal response to frontline chemotherapy and without established second line treatment. cMET activation is associated with ACC resistance to chemotherapy. Cabozantinib is a multi-kinase inhibitor that targets the VEGFR,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bedrose, Sara Shokry Daniel, Altameemi, Lina, Daher, Marilyne, De Rosa, Gina Tamsen, Varghese, Jeena Mary, Jimenez, Camilo, Campbell, Matthew, Habra, Mouhammed Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209711/ http://dx.doi.org/10.1210/jendso/bvaa046.508

Ejemplares similares

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions
por: Bedrose, Sara, et al.
Publicado: (2020)

RF19 | PSUN33 Adrenocortical Carcinoma as a Rare Manifestation of Birt-Hogg-Dubé Syndrome
por: Else, Tobias, et al.
Publicado: (2022)

PSAT010 Severe Cholestatic Jaundice (Stauffer Syndrome) as a Rare Paraneoplastic Manifestation in Adrenocortical Carcinoma
por: Murvelashvili, Natia, et al.
Publicado: (2022)

FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry
por: Brondani, Vania B, et al.
Publicado: (2023)

SAT-207 Adrenocortical Carcinoma in Untreated Congenital Adrenal Hyperplasia
por: David, Julia, et al.
Publicado: (2020)

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
por: Habra, Mouhammed Amir, et al.
Publicado: (2021)

SAT-350 Comparative Proteomic Analysis of Various Forms of Bilateral Adrenocortical Hyperplasia
por: Berthon, Annabel, et al.
Publicado: (2019)

SAT-172 FDG PET/CT in Benign vs. Malignant Adrenocortical Tumors
por: He, Xin, et al.
Publicado: (2020)

SAT-180 Adrenocortical Carcinoma - A Tertiary Center’s Recent 5-Year Experience
por: Ehrenwald, Michal, et al.
Publicado: (2020)

SAT-354 Characterization of Cell Death Induced by SOAT1 Inhibition in Adrenocortical Carcinoma Cells
por: Weigand, Isabel, et al.
Publicado: (2019)

SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019)

SAT-165 Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma
por: Lacombe, Amanda Meneses Ferreira, et al.
Publicado: (2020)

SAT-179 Increased Telomere Length in Adrenocortical Tumors Is Associated with Abnormal Expression of Chromatin Remodelling Factors
por: Stecchini, Monica F, et al.
Publicado: (2020)

SAT-178 Incidence, Patterns of Clinical Presentation, and Outcomes of Patients with Brain Metastasis Due to Adrenocortical Carcinoma
por: Amorim, Larissa Costa, et al.
Publicado: (2020)

SAT-173 SAMD9 (Sterile Alpha Motif Domain-Containing 9) Expression in Adrenocortical Tumors
por: Bueno, Ana C, et al.
Publicado: (2020)

SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors
por: Pereira, Sofia, et al.
Publicado: (2019)

SAT-171 Adrenocortical Carcinoma in Thailand: A 10-Year Retrospective Review in a Single Tertiary Center
por: Gomutput, Patrawon, et al.
Publicado: (2020)

SAT-359 Involvement of Inflammation and Oxidative Stress in the Adrenocortical Dysfunction Displayed by Insulin Resitant Rats: Effect of Hemin Treatment
por: Vecino, Carolina, et al.
Publicado: (2019)

SAT-LB44 WNT2B Regulates Adrenocortical Progenitor Cell Fate And Zona Glomerulosa Identity In Vivo
por: Little, Donald W, et al.
Publicado: (2020)

SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
por: Mohan, Dipika R, et al.
Publicado: (2020)

SAT-LB36 Distinct Vitamin D Receptor DNA Methylation Profiles Are Associated With the Outcome of Pediatric Patients With Adrenocortical Tumors
por: Bueno, Ana Carolina, et al.
Publicado: (2020)

SAT-353 The Synthetic Vitamin D Analog EB1089 Restricts Adrenocortical Tumor Proliferation in NCI-H295 Xenograft Model
por: Bueno, Ana, et al.
Publicado: (2019)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

SAT-169 Adrenocortical Cancer Is Diagnosed at Large Size and Advanced Stage in a Canadian Referral Center; Focus on Modes of Presentation Depending on Stages
por: Poirier, Jonathan, et al.
Publicado: (2020)

SAT-158 New Data on High Prevalence and Time of Occurrence of New Onset Hypothyroidism Associated with Mitotane Therapy in a Cohort of Adrenocortical Cancer
por: Poirier, Jonathan, et al.
Publicado: (2020)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

SAT-155 High Prevalence Alterations on DNA Mismatch Repair Genes Related to Lynch Syndrome in Pediatric Patients with Adrenocortical Tumor Carried of the Germline Mutation on TP53
por: Brondani, Vânia Balderrama, et al.
Publicado: (2020)

MON-175 Structural Instability as an Underlying Pathomechanism in Congenital Adrenal Hyperplasia
por: Meese, Nicolas, et al.
Publicado: (2020)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

SAT-193 Clinical Case of ARMC5 Tumor Syndrome: A Rare Case of Cushing’s Syndrome from Primary Bilateral Macronodular Adrenal Hyperplasia Caused by ARMC5 Mutation with Concomitant Presence of Meningiomas and Primary Hyperparathyroidism
por: Parikh, Sahil, et al.
Publicado: (2020)

SAT-194 Pheochromocytoma During Pregnancy: A Ticking Time Bomb
por: Sarmiento-Ramon, Juan Camilo, et al.
Publicado: (2020)

SAT-229 Bilateral Pheochromocytoma as Incidental Finding in a Patient with Neurofibromatosis Type 1
por: Herrera, Raul A, et al.
Publicado: (2020)

SAT281 Screening For Adrenocortical Insufficiency In Patients With X-linked Adrenoleukodystrophy
por: Berquist, John, et al.
Publicado: (2023)

Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
por: Guiomar, Joana Reis, et al.
Publicado: (2021)

SAT-226 Lifestyle Modifications or Adrenalectomy? Pheochromocytoma Presenting with New Onset Diabetes Mellitus
por: Sosa-Pagan, Max, et al.
Publicado: (2020)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

PSUN13 Transcriptional and epigenetic landscapes of adrenocortical tumors
por: Lerario, Antonio, et al.
Publicado: (2022)

SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
por: Tirosh, Amit, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_94hgqa0ub1kiq2o1bauv9t6s97